The hematopoietic growth factors in the myelodysplastic syndromes

  • Ortega J
  • Komrokji R
  • List A
  • 2


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


The myelodysplastic syndromes (MDSs) are a heterogeneous group of hematopoietic stem cell malignancies that are characterized by abnormal morphology and impaired bone marrow maturation resulting in progressive cytopenia(s) and a propensity to evolve into acute myeloid leukemia (AML) [1]. The biologic hallmark of the hematopoietic stem cells in MDS is a defective capacity for self-renewal and differentiation. Predisposition to MDS is amplified in the elderly because of senescence-associated depletion of stem cells and associated changes in the marrow microenvironment that may foster ineffective hematopoiesis and may also favor the development of secondary clones [2]. © 2011 Springer Science+Business Media, LLC.

Author-supplied keywords

  • *myelodysplastic syndrome/di [Diagnosis]
  • *myelodysplastic syndrome/dm [Disease Management]
  • *myelodysplastic syndrome/dt [Drug Therapy]
  • *myelodysplastic syndrome/ep [Epidemiology]
  • *myelodysplastic syndrome/et [Etiology]
  • *myelodysplastic syndrome/th [Therapy]
  • *recombinant growth factor/cm [Drug Comparison]
  • *recombinant growth factor/dt [Drug Therapy]
  • 5 aza 2' deoxycytidine/dt [Drug Therapy]
  • acute granulocytic leukemia
  • algorithm
  • allogeneic stem cell transplantation
  • aplastic anemia/si [Side Effect]
  • arthralgia/si [Side Effect]
  • azacitidine/dt [Drug Therapy]
  • blood cell count
  • cancer epidemiology
  • cancer survival
  • cardiovascular disease/si [Side Effect]
  • cell differentiation
  • deferasirox/dt [Drug Therapy]
  • deferasirox/pe [Pharmacoeconomics]
  • deferasirox/po [Oral Drug Administration]
  • disease classification
  • disease course
  • drug cost
  • drug dose escalation
  • drug dose increase
  • drug fatality/si [Side Effect]
  • drug fever/si [Side Effect]
  • drug half life
  • drug hypersensitivity/si [Side Effect]
  • drug potentiation
  • drug response
  • drug withdrawal
  • eltrombopag/ct [Clinical Trial]
  • eltrombopag/dt [Drug Therapy]
  • eltrombopag/pd [Pharmacology]
  • eltrombopag/po [Oral Drug Administration]
  • erythrocyte transfusion
  • fatigue/si [Side Effect]
  • flu like syndrome/si [Side Effect]
  • fluid retention
  • genetic predisposition
  • hematopoiesis
  • hematopoietic stem cell
  • human
  • hypertension/si [Side Effect]
  • idiopathic thrombocytopenic purpura/dt [Drug Thera
  • immunosuppressive agent/dt [Drug Therapy]
  • incidence
  • karyotype
  • kidney failure/si [Side Effect]
  • lenalidomide/cb [Drug Combination]
  • lenalidomide/dt [Drug Therapy]
  • lenalidomide/po [Oral Drug Administration]
  • methyltransferase inhibitor/dt [Drug Therapy]
  • myeloblast
  • neutropenia
  • neutrophil count
  • novel erythropoiesis stimulating protein/ae [Adver
  • novel erythropoiesis stimulating protein/cb [Drug
  • novel erythropoiesis stimulating protein/cm [Drug
  • novel erythropoiesis stimulating protein/ct [Clini
  • novel erythropoiesis stimulating protein/do [Drug
  • novel erythropoiesis stimulating protein/dt [Drug
  • novel erythropoiesis stimulating protein/pe [Pharm
  • novel erythropoiesis stimulating protein/pk [Pharm
  • novel erythropoiesis stimulating protein/sc [Subcu
  • overall survival
  • pomalidomide/cb [Drug Combination]
  • pomalidomide/dt [Drug Therapy]
  • priority journal
  • prognosis
  • recombinant erythropoietin/ae [Adverse Drug Reacti
  • recombinant erythropoietin/cb [Drug Combination]
  • recombinant erythropoietin/cm [Drug Comparison]
  • recombinant erythropoietin/ct [Clinical Trial]
  • recombinant erythropoietin/do [Drug Dose]
  • recombinant erythropoietin/dt [Drug Therapy]
  • recombinant erythropoietin/it [Drug Interaction]
  • recombinant erythropoietin/pd [Pharmacology]
  • recombinant erythropoietin/sc [Subcutaneous Drug A
  • recombinant granulocyte colony stimulating factor/
  • recombinant granulocyte macrophage colony stimulat
  • recombinant interleukin 11/ae [Adverse Drug Reacti
  • recombinant interleukin 11/ct [Clinical Trial]
  • recombinant interleukin 11/dt [Drug Therapy]
  • recombinant interleukin 6/ae [Adverse Drug Reactio
  • recombinant interleukin 6/ct [Clinical Trial]
  • recombinant interleukin 6/dt [Drug Therapy]
  • recombinant thrombopoietin/ae [Adverse Drug Reacti
  • recombinant thrombopoietin/dt [Drug Therapy]
  • refractory anemia
  • refractory anemia with excess blasts
  • refractory anemia with ringed sideroblasts
  • refractory cytopenia with multilineage dysplasia
  • refractory thrombocytopenia
  • review
  • risk assessment
  • romiplostim/ae [Adverse Drug Reaction]
  • romiplostim/ct [Clinical Trial]
  • romiplostim/do [Drug Dose]
  • romiplostim/dt [Drug Therapy]
  • side effect/si [Side Effect]
  • single drug dose
  • skin manifestation/si [Side Effect]
  • survival time
  • thrombocyte count
  • thrombocytopenia/si [Side Effect]
  • thromboembolism/si [Side Effect]
  • treatment response
  • unspecified side effect/si [Side Effect]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • J Ortega

  • R Komrokji

  • A F List

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free